Transcenta Holding Limited (6628.HK)

1,520 +0,020 (+1,33 %) À la clôture : 04:08PM HKT

Transcenta Holding Limited

B6-501, 218 Xinghu Street
Biobay
Suzhou 215123
China
86 21 6237 0929
https://www.transcenta.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 215

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Xueming Qian Ph.D.	CEO & Executive Chairman	3,5M	S.O.	1969
Mr. Xiaolu Weng CPA	Executive VP & CFO	3,73M	S.O.	1977
Dr. Feng Ye Ph.D.	Executive VP & COO	S.O.	S.O.	1969
Dr. Christopher Hwang Ph.D.	Executive VP & CTO	S.O.	S.O.	1965
Ms. Wei Wang	VP of Investor Relations & Capital Markets Department and Secretary to the Board	S.O.	S.O.	1983
Dr. Yi Gu Ph.D.	Senior VP & Head of Research	S.O.	S.O.	1969
Dr. Charlie Qi M.D.	Senior Vice President of Global Clinical Development	S.O.	S.O.	S.O.
Dr. Xichen Zhang Ph.D.	Senior Vice President of Manufacturing	S.O.	S.O.	S.O.
Dr. Wen-I Chang Ph.D.	Senior Vice President of Oncology Franchise Strategy	S.O.	S.O.	S.O.
Dr. Caroline Germa M.D., Ph.D.	Executive VP of Global Medicine Development & Chief Medical Officer	S.O.	S.O.	1972

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en HKD.

Description

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST005, a PD-L1/TGF-ß bi-functional protein candidate for solid tumors; TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing; TST003, a regulatory protein expressed by stromal cells and tumor cells, including colon, prostate, gastric, lung, esophageal, pancreatic, and breast cancers; TST006, a bi-specific claudin 18.2/PD-L1 antibody for solid tumors; TST008, a bi-functional antibody for MASP-2 and BAFF for autoimmune diseases; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors; MSB2311, A humanized PD-L1 mAb candidate for solid tumors; TST012 and TST013, an ADC candidate targeting biomarker expressing gastric cancer and other solid tumors; and TST801, a bifunctional fusion protein for autoimmune diseases. The company has a partnership and collaboration agreements with Bristol Myers Squibb and Eli Lilly & Company; research collaboration with Alebund Pharmaceuticals, Dana Farber Cancer Institute, and John Hopkins University; and technology collaboration with Merck KGaA. The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019. Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People's Republic of China.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Transcenta Holding Limited en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.